1
EPISODE · May 23, 2026 · 11 MIN
Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients
from 1nessAgency Insights
Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa
Embed this episode
NOW PLAYING
Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients
0:00
11:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 1nessAgency Insights?
This episode is 11 minutes long.
When was this 1nessAgency Insights episode published?
This episode was published on May 23, 2026.
Can I download this 1nessAgency Insights episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!